35 results about "Chilblain lupus erythematosus" patented technology

This invention related to methods and assays for screening for, identifying, and predicting the severity and clinical manifestations of systemic lupus erythematosus (SLE). Specifically, this invention provides various biomarkers for the prediction of flares of the disease both in number and severity, as well as clinical manifestations of the disease, and methods of using these biomarkers to correctly subclassify patients with this disease, and prescribe appropriate treatment. The invention also provides for biomarkers of lupus disease activity, i.e., flares, as well as biomarkers for the prediction of future flares, and methods of using these biomarkers. The invention also provides, in these biomarkers, targets and methods for drug development and basic research for SLE.

Provided is a treating method for circular RNA in systemic lupus erythematosus. The treating method comprises the following steps that a systemic lupus erythematosus group, a rheumatoid arthritis group and a normal control group are set, each group comprises a plurality of parts of whole blood samples which are detached from the human body of different human bodies, , peripheral blood mononuclear cells are obtained by separating correspondingly; total RNA in all peripheral blood mononuclear cells is extracted correspondingly; ribonucleic acid labeling and chip hybridization are conducted; and the fluorescence intensity of a chip after hybridization is scanned, the obtained chip scanning result is analyzed, and circular RNA differently expressed between the systemic lupus erythematosus group and the normal control group as well as the systemic lupus erythematosus group and the rheumatoid arthritis group is sieved. According to the treating method for the circular RNA in the systemic lupus erythematosus, circ RNA abnormally expressed by the systemic lupus erythematosus is obtained and can serve as a potential diagnostic marker for the systemic lupus erythematosus, and sufficient theoretical basis for studying pathogenesis of the systemic lupus erythematosus can be further provided.

The invention relates to a diagnostic marker for systemic lupus erythematosus, and in particular discloses application of a reagent for specific detection of high mannose type N-linked carbohydrate chain level in a serum antibody to preparation of a diagnostic tool for diagnosis and/or prognosis assessment of systemic lupus erythematosus. The increase of the high mannose type N-linked carbohydrate chain level in the serum antibody is closely related to the occurrence of systemic lupus erythematosus. Therefore, the diagnostic marker can be used for early diagnosis and/or prognostic assessment of systemic lupus erythematosus, and further can be used for guiding treatment of systemic lupus erythematosus.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The invention provides a product for treating systemic lupus erythematosus and rheumatism and a preparation method thereof, and belongs to the field of Chinese patent medicine and pharmacy technology thereof. The invention is characterized in that the product is obtained from common submerged fermentation of a water extract of the following traditional Chinese medicines and a morel mother strain: 20-40 parts of radix clematis, 20-40 parts of Ligusticum wallichii, 20-40 parts of madder, 20-40 parts of late silkworm excrement, 20-40 parts of red adzuki beans, 20-40 parts of angelica, 20-40 parts of cinnamon and 20-40 parts of semen allii tuberosi. In some embodiments, a fetus cervi powder is added in the submerged fermentation, so that the product is rich in plant polypeptides from traditional Chinese medicines. Fungus polysaccharide of the morel, animal polysaccharide from the fetus cervi powder and coordination compounds of the three polysaccharides have substantial effects on integrally enhancing immunity of the patients. The product provided by the invention can simultaneously treat principal and subordinate symptoms, and have no toxic or side effect, and fast effectiveness.

The invention discloses a Chinese traditional medicine capsule for treating lupus erythematosus and a preparation method of the Chinese traditional medicine capsule. The Chinese traditional medicine capsule for treating lupus erythematosus is characterized in that the raw materials comprise 15-45 parts by weight of peeled thunder god vine with removed roots, 15-45 parts by weight of leatherleaf milletia and 15-45 parts by weight of sargentgloryvine stem. The invention also provides a preparation method of the Chinese traditional medicine capsule for treating lupus erythematosus. According to the invention, the effective ingredients of the three raw material medicines can be effectively extracted, and the prepared capsule has a better effect than the original three-rattan mixture; and the quality can be effectively controlled, the capsule is convenient to take and carry, and the storage time is longer.

The invention discloses a Chinese patent medicine for treating discoid lupus erythematosus, which belongs to the technical field of treatment of skin diseases. The Chinese patent medicine is prepared from the following Chinese medicinal herbs in parts by weight: 10-20 parts of rehmanniae praeparatum, 15-25 parts of red paeony root, 15-25 parts of achyranthis bidentatae, 20-30 parts of dandelion, 20-30 parts of Chinese violet, 30-40 parts of red-rooted salvia, 15-25 parts of pollen, 15-25 parts of angelica, 15-25 parts of white paeony root, 15-25 parts of fructus forsythia, 15-25 parts of scutellaria, 10-15 parts of liquorice, 8-12 parts of dipsacus asperoides, 9-16 parts of scrophularia, 15-25 parts of cortex lycii radicis, 15-25 parts of Sophora flavescens, 10-20 parts of antelope horn, 10-20 parts of duckweed and 10-20 parts of rhizoma alismatis. Compared with the prior art, the Chinese patent medicine for treating the discoid lupus erythematosus has outstanding substantial characteristics and obvious advantages of removal of the diseases of patients, promotion of physical and psychological health, convenience for taking, quick therapeutic effect and no side effect.

The invention discloses a polypeptide SLE2018-V001 for use in diagnosing a systemic systemic lupus erythematosus kit. The amino acid sequence of the polypeptide SLE2018-V001 is: YEHAMYRSAVLL. The invention adopts the enzyme linked immunosorbent assay (ELISA) technology widely used in clinical practice, and uses an indirect method to qualitatively detect the level of IgG antibody against anti-YEHAMYRSAVLL polypeptide in human serum. The kit of the present invention can greatly improve the specificity and sensitivity of the early diagnosis of the systemic lupus erythematosus as an aid in the early diagnosis of the systemic lupus erythematosus, with a specificity of 74% and a sensitivity of 88%.

The invention discloses a traditional Chinese medicine for treating lupus erythematosus. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-18 parts of white paeony root, 20-30 parts of radix rehmanniae preparata, 20-30 parts of astragalus membranaceus, 15-25 parts of cassia bark, 20-30 parts of largetrifoliolious bugbane rhizome, 25-35 parts of Chinese thorowax root, 10-20 parts of safflower, 12-18 parts of donkey-hide glue, 10-16 parts of raw oyster shell, 10-16 parts of raw turtle shell, 8-15 parts of raw tortoise plastron and 6-10 parts of white mulberry root-bark. The traditional Chinese medicine for treating lupus erythematosus, disclosed by the invention, adopts Chinese thorowax root as a main medicament, other auxiliary medicaments are matched, and the main medicament and the auxiliary medicaments act upon each other and have synergistic effects, so that the traditional Chinese medicine can play good roles in conditioning and tonifying the five internal organs, reinforcing qi and nourishing blood, soothing the liver and regulating qi circulation, and improving immunity, has a very good curative effect on lupus erythematosus, and is simple in raw material and convenient to take.

The invention discloses application of anti-CarP (Carbamylated protein) antibodies as a systemic lupus erythematosus (SLE) diagnostic marker and belongs to the technical field of immune medicine. Theanti-CarP antibodies in a systemic lupus erythematosus patient are clearly increased. Through utilization of direct relevance between the anti-CarP antibodies and systemic lupus erythematosus, the systemic lupus erythematosus can be diagnosed accurately. The anti-CarP antibodies have wide clinical diagnosis application value. The SLE patient can be identified well from people who are healthy through detection of other detection methods. The anti-CarP antibodies are taken as supplement of other specific antibodies of the SLE, so an SLE detection positive rate is improved. The anti-CarP antibodies are related to various clinical and laboratory indexes, this hints that the anti-CarP antibodies may effectively predict disease activity.

The invention relates to an application of hemsley rockvine root tuber in treating lupus erythematosus. The application is characterized in that a medicine used for treating lupus erythematosus comprises hemsley rockvine root tuber. The medicine can be prepared into any medical preparation with traditional Chinese medicine preparation methods. An effective dose for a patient a day is 3-500g. The medicine provided by the invention has a substantial effect in treating lupus erythematosus and no side effect.

The invention discloses a Chinese patent medicine for treating deep lupus erythematosus and belongs to the technical field of skin disease treatment. According to the technical scheme provided by the invention, the Chinese patent medicine is made from the following medicaments of: by weight, 20-30 parts of fleece-flower root, 15-25 parts of radix paeoniae rubrathe, 15-25 parts of Cortex moutan, 15-25 parts of achyranthcs bidentata blume, 20-30 parts of cornus officinalis, 20-30 parts of Yedo violet, 20-30 parts of Radix Codonopsis, 15-25 parts of Chinese cassia tree, 15-25 parts of Chinese angelica, 15-25 parts of white peony root, 15-25 parts of wolfberry, 15-25 parts of scutellaria baicalensis, 10-15 parts of eucommia, 15-25 parts of lithospermum, 9-16 parts of red sage root, 10-15 parts of Rhizoma anemarrhenae, 10-15 parts of sophora flavescens, 10-20 parts of cornu saigae tataricae, 10-20 parts of duckweed and 10-20 parts of Alisma Orientalis. In comparison with the prior art, the Chinese patent medicine for treating deep lupus erythematosus has effects of eliminating patients' diseases and promoting physical and mental health, is convenient for patients to take, and has outstanding substantive characteristics and marked progress of fast curative effect and no side-effect.

The invention discloses externally applied traditional Chinese medicine for treating systematic lupus erythematosus. The externally applied traditional Chinese medicine comprises, by weight, 9-10 parts of dried rehmannia roots, 3-4 parts of radix cyathulae, 2-4 parts of glossy privet leaves, 5-7 parts of scutellaria barbata, 4-5 parts of herba taxilli, 8-10 parts of fructus arctii, 2-4 parts of folium isatidis, 5-6 parts of celastrus angulata maxim, 3-5 parts of rhizoma menispermi, 2-4 parts of saruma henryi, 5-8 parts of harlequin glorybower leaves, 4-5 parts of palm bark, 2-4 parts of hedyotis diffusa, 1-3 parts of saussurea japonica, 2-4 parts of herba fibraureae recisae leaves, 1-2 parts of Chinese pearleaf crabapple leaves and 4-5 parts of goldhair hedyotis herb. The externally applied traditional Chinese medicine has the advantages that stasis removing, blood cooling, heat clearing, toxicity removing, healthy qi strengthening and pathogen eliminating effects can be realized by the traditional Chinese medicine composition, effects of eliminating pathogen without harming the healthy qi and strengthening the healthy qi without retaining the pathogen can be realized, good treatment effects can be realized when the externally applied traditional Chinese medicine is clinically used for treating the systematic lupus erythematosus, and the externally applied traditional Chinese medicine is low in recurrence rate and free of toxic and side effects.

The invention provides a traditional Chinese medicine composition for treating lupus erythematosus. The composition is prepared from campsis grandiflora, abrotani herba, leech, curcuma zedoary, paris polyphylla, radices lithospermi, moutan bark, raspberry, abutilon indicum, pseudo-ginseng, caulis spatholobi, cuscuta chinensis, pinellia ternata, lalang grass rhizome, gentiana macrophylla, selfheal, rhizoma drynariae, philippine violet herb, rhizoma cimicifugae, agastache rugosa, tribulus terrestris, cirsium japonicum, gynostemma pentaphyllum, ligusticum wallichii, cortex mori radicis, coptis chinensis, semen plantaginis, glossy privet fruit, liquidambar formosana hance, epimedium and licorice root. The traditional Chinese medicine composition is reasonable in formula, and the medicinal materials are combined to achieve the effects of strengthening the body resistance to eliminate pathogenic factors, dispelling wind, drying dampness, promoting blood circulation to remove stasis and regulating yin and yang. The traditional Chinese medicine composition has the advantages of good effect and low recurrence rate, can be used for treating both symptoms and root causes, and can be used for effectively relieving pains of patients.

The invention relates to decoction medicine for treatingsystemic lupus erythematosus and a preparation method of the decoction medicine. The medicine comprises the following ingredients in parts by mass: 1 to 3 parts of astragalus, 1 to 3 parts of zaocys dhumnade, 1 to 3 parts of sealwort, 1 to 3 parts of spatholobus stem, 1 to 3 parts of gentiana macrophylla, 1 to 3 parts of salvia miltiorrhiza, 1 to 3 parts of lotus plumule, 1 to 3 parts of polygonatum, 1 to 3 parts of radix ginseng alba, 1 to 3 parts of radix paeoniae alba, 1 to 3 parts of angelica, 1 to 3 parts of glossy privet fruits, 1 to 3 parts of sichuan coptis roots and 1 to 3 parts of rehmannia glutinosa. The preparation method of the medicine comprises the following steps of selecting and buying high-quality and clear first-grade astragalus, zaocys dhumnade, sealwort, spatholobus stem, gentiana macrophylla, salvia miltiorrhiza, lotus plumule, polygonatum, radix ginseng alba, radix paeoniae alba, angelica, glossy privet fruits, sichuan coptis roots and rehmannia glutinosa according to the mass part ratio; respectively removing impurities and dust; then putting the medicine into a cloth bag; binding the opening for use; putting the medicine into cold boiled water; soaking the medicine for about half an hour until the medicine tissues are permeated; then putting the soaked medicine and clarified liquid for soaking the medicine into a medicine decoration machine; injecting the cold boiled water being 34mm exceeding the medicine; performing primary decoration and boiling for 35 minutes; filtering medicine liquid; injecting slight warm boiled water being 30 mm exceeding the medicine; performing secondary decoration and boiling for 30 minutes; performing mixing and concentration to obtain 1620ml of 50-percent traditional Chinese medicine liquid for use.

The invention relates to a Chinese medicament for treating lupus erythematosus, which is prepared from 12 gouts of Chinese medicaments, namely rhubarb, root of rehmannia, baikal skullcap root, Mongolian snakegourd root, chicken's gizzard-membrane, figwort root, antelope horn, medicated leaven, thunder god vine, licorice root, dwarf lilyturf tuber and dahurian angelica root. The Chinese medicament can improve the immune function of the human body, activate cells of the human body and clear toxin effect in the body, has no toxic or side effect, treats the root cause and symptoms of diseases, has remarkable curative effect and quick clinical symptom dissolution, has prevention and treatment effect on the lupus erythematosus, and has no relapse after healing.

A traditional Chinese medicine preparation for treating lupus erythematosus. The following traditional Chinese medicine proportioning formula is adopted: 15 parts of three stamens grass, 25 parts of Ligustrum lucidum seed, 15 parts of Cuscuta seed, 15 parts of Achyranthes bidentata, 10 parts of Cervus cerevisiae, and Hedyotis diffusa 15 parts, 13 parts of Poria cocos, 13 parts of Gentiana chinensis, 13 parts of comfrey. The positive effect of the invention is that the preparation is made of pure Chinese herbal medicine, has high curative effect on lupus erythematosus, treats both symptoms and root causes, has remarkable curative effect, has no adverse reaction, has little toxic and side effects, clinical symptoms disappear quickly, and there is no rebound phenomenon after being cured.

The invention discloses a traditional Chinese medicine formula for treating arthralgia caused by lupus erythematosus. The traditional Chinese medicine is characterized by being prepared from, by weight, 30-35 g of humulus scandens, 12-15 g of radix pseudostellariae, 12-15 g of radix asparagi, 12-15 g of fiveleaf akebia fruit, 15-20 g of rhizoma atractylodis and rhizoma atractylodis macrocephalae, 25-30 g of rhizoma smilacis glabrae, 12-15 g of lotus leaves, 15-20 g of dioscorea opposite, 12-15 g of cortex ailanthi, 12 g of celosia cristata, 15 g of cassia twigs and radix paeoniae alba and 30 g of fossilia ossia mastoid and raw oysters. The traditional Chinese medicine formula for treating the arthralgia caused by the lupus erythematosus has the effects of relieving the arthralgia and reducing facial erythema.

The invention relates to a traditional Chinese medicine formula for treating lupus erythematosus. The formula is composed of 7-12 grams of comfrey, 7-12 grams of Atractylodes macrocephala, 7-12 grams of clematis, 3-9 grams of skullcap, and Achyranthes bidentata 3-9 grams, 10-15 grams of Daqingye, 15-20 grams of raw land, 10-15 grams of angelica, 13-19 grams of Sanfensan, 15-20 grams of Artemisia annua, 8-12 grams of burdock, and 4 -9 grams.

The invention discloses an external traditional Chinese medicine for treating facial lupus erythematosus. The external traditional Chinese medicine is composed of the following raw materials in parts by weight: 4 to 6 parts of sticktight, 8 to 10 parts of Chinese violet, 7 to 8 parts of coptis, 3 to 5 parts of prepared frankincense, 2 to 4 parts of myrrh, 10 to 12 parts of dried orange peel, 6 to 7 parts of spatholobus stem, 2 to 3 parts of garden burnet leaf, 5 to 7 parts of lithospermum, 8 to 9 parts of calcined gypsum, 2 to 4 parts of mantis egg-case, 4 to 6 parts of lucid ganoderma, 6 to 8 parts of tribulus terrestris, 15 to 20 parts of wild chrysanthemum, 4 to 5 parts of red peony root, 2 to 4 parts of cirsium japonicum, 6 to 8 parts of umbellate rock jasmine, and 3 to 4 parts of eomecon chionantha. Multiple of wild traditional Chinese herbals are adopted as the raw materials, the raw materials cooperate with each other to generate a synergetic effect, the external traditional Chinese medicine has the functions of clearing heat, removing toxicity, activating blood, resolving stasis, softening the hardness, and dissipating the binds, has a good effect on treating facial lupus erythematosus, and does not have any side or toxic effect, and the cure rate can reach at least 85%.

The invention discloses a traditional Chinese medicine formula for treating lupus erythematosus, which comprises the following Chinese medicinal ingredients in parts by weight: 16g of dendrobium, 16g of Nansha ginseng, 16g of northern sand ginseng, 16g of trichosanthemi rhizome, 28g of rhizome of rhizoma radix, 16g of eclipta, and 16g of Digupi , Astragalus 16g, Radix Pseudostellariae 16g, Polygonatum 8g, Salvia miltiorrhiza 16g, Caulis Spatholobus 28g, Gentiana chinensis 28g, black snake 8g, Chonglou 16g, Hedyotis diffusa 28g. The preparation and use method of the traditional Chinese medicine composition of the present invention: first soak the medicinal material with clear water for 1 hour, the amount of soaked water is preferably 3cm to submerge the surface of the medicine, boil it with strong fire, decoct it with slow fire for 30 minutes after boiling, pour the medicinal liquid After decocting for the second time, add 2cm of hot water that has just submerged the medicinal residues, decoct for 30 minutes, pour out the medicinal liquid, mix the 2 medicinal liquids into 1 dose, take 1 dose per day, and take it warmly in the morning and evening.